alexa Antimetastatic efficacy of orally administered ginsenoside Rb1 in dependence on intestinal bacterial hydrolyzing potential and significance of treatment with an active bacterial metabolite.
Psychiatry

Psychiatry

Journal of Addiction Research & Therapy

Author(s): Hasegawa H, Uchiyama M

Abstract Share this page

Abstract The antimetastatic effects of orally administered ginsenoside Rb1 (Rb1) and an active metabolite by intestinal bacteria, 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol (I), were studied, by using a spontaneous metastasis model produced by subcutaneous injection of Lewis lung carcinoma (LLC) in syngeneic C57BL/6 mice. A thorough analysis of the hydrolyzing potential (transformation by intestinal bacteria) was first done and the data found were positively correlated to the antimetastatic effect of Rb1 through the medium of I. The transformation rate by 41\% fecal specimens was less than 10\% and consecutive Ginseng administrations were ineffective for the mice with hydrolyzing potential of less than 10\%, which limited the antimetastatic efficacy of Rb1- In contrast, the efficacy of I was greater than that of Rb1 and at least comparable to that of S-FU. No effect of I on the primary tumor growth was found, indicating a specific antimetastatic activity. In a leg amputation model with the LLC-line, an effect on survival time of I (8 mg/kg/day) equal to that of 5-FU (10 mg/kg/day) was seen and 38\% mice were cured as compared with 13\% cured by amputation alone. These findings suggest that the active drug is the bacterial metabolite I which should be administered rather than Rb1. This article was published in Planta Med and referenced in Journal of Addiction Research & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords